Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778937 | 0.83 | HTR1A (0.58) | HTR1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4779156 | 0.82 | HTR1A (0.51) | HTR1ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL4725380 | 0.77 | HTR1A (0.57) | HTR1ASMN1; SMN2 | |
| SCHEMBL4725646 | 0.77 | HTR1A (0.63) | HTR1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5745668 | 0.74 | HTR1A (0.63) | HTR1ASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL4726821 | 0.74 | HTR1A (0.55) | HTR1ASMN1; SMN2 | |
| SCHEMBL4727354 | 0.73 | PIM1 (0.41) | HTR1AALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL4252076 | 0.73 | HTR1A (0.72) | HTR1ASMN1; SMN2 | |
| SCHEMBL4252077 | 0.73 | HTR1A (0.72) | HTR1ASMN1; SMN2 | |
| SCHEMBL4239583 | 0.67 | SMN1; SMN2 (0.66) | HTR1ASMN1; SMN2ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351732-B2 | Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications | SCHWARZ PHARMA S.L. (DE) | 2008-04-01 | — | — | US | claimed |
| US-7351732-B2 | Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications | SCHWARZ PHARMA S.L. (DE) | 2008-04-01 | — | — | US | disclosed |
| WO-2008015538-A2 | USE OF DIAZA- AND THIAZA-CYCLOALKANEDIONES FOR PREVENTING AND/OR TREATING PAIN AND /OR MIGRAINE | SCHWARZ PHARMA S.L. (ES) | 2008-02-07 | — | — | WO | disclosed |
| US-20050250777-A1 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications | SCHWARZ PHARMA S.L. (DE) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250777-A1 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications | HTR3A, HTR1A, HTR5A | HTR1A 2/4885SMN1; SMN2 3292/4885ALDH1A1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.